Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Bruce Rashbaum

Internal Medicine Washington, DC Medical Doctor

NPI 1568555456 CMS profile 298002

2300 M St Nw Ste 910, Washington, DC 20037

Open in the dashboard

General payments

$85,718

242 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$179,204 paid to institutions, not to them · program year 2019

Through program year 2021, Bruce Rashbaum of Washington, DC is reported in the CMS Open Payments database as having received $85,718 across 242 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $179,204 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $63 3
2020 General $4,495 39
2019 General $81,160 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Rashbaum
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bruce Rashbaum were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bruce Rashbaum Internal Medicine median Middle half National median
2019 $81,160 $159 $48–$570 $163
2020 $4,495 $119 $33–$402 $114
2021 $63 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Gilead Sciences, Inc. $67,043 105 payments
  2. Janssen Products, LP $15,972 20 payments
  3. Janssen Biotech, Inc. $800 32 payments
  4. Medicure Pharma Inc. $300 1 payment
  5. Theratechnologies Inc. $272 12 payments
  6. Merck Sharp & Dohme Corporation $189 14 payments
  7. Amgen Inc. $182 5 payments
  8. Kowa Pharmaceuticals America, Inc. $178 10 payments
  9. Novo Nordisk Inc $97 5 payments
  10. ViiV Healthcare Company $93 4 payments
  11. Other $592 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,450 26 payments
  2. Travel and Lodging $14,890 29 payments
  3. Food and Beverage $4,864 185 payments
  4. Consulting Fee $4,510 1 payment
  5. Education $4 1 payment
Products named General payments · program years 2019–2021
  1. Biktarvy $27,138 34 payments
  2. SYMTUZA $16,726 50 payments
  3. HMG-CoA reductase inhibitor $300 1 payment
  4. TROGARZO $272 12 payments
  5. EGRIFTA $255 11 payments
  6. Repatha $182 5 payments
  7. Bystolic $178 10 payments
  8. Livalo $178 10 payments
  9. PIFELTRO $102 7 payments
  10. ISENTRESS $102 7 payments
  11. Other $1,468 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record